ACTG A5030-VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV) VIREMIA

ACTG A5030-缬更昔洛韦预防巨细胞病毒 (CMV) 病毒血症

• 批准号: 7604373
• 负责人: THOMAS A CAMPBELL
• 金额: $ 0.12万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604373
• 关键词: CD4 Lymphocyte Count; Cells; Computer Retrieval of Information on Scientific Projects Database; Cytomegalovirus; Disease; Funding; Grant; HIV; HIV Infections; Institution; Organ; Persons; Plasma; Prophylactic treatment; Purpose; RNA; Research; Research Personnel; Resources; Risk; Source; United States National Institutes of Health; Valganciclovir; Viremia; antiretroviral therapy; prevent; tv watching

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to find out whether treatment with valganciclovir is safe and effective in preventing CMV organ damage in persons with HIV infection at risk for CMV disease. Eligible subjects will be CMV seropositive, currently receiving no CMV prophylaxis, with no evidence of CMV end organ disease, have a CD4 cell count <100 cells/ mm3, and a plasma HIV RNA >400 copies/mL. Subjects must either have, at time of screening, been receiving antiretroviral therapy continuously for >3 months or not be receiving antiretroviral therapy and not planning to initiate antiretroviral therapy for at least 3 months after entering the study.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 该研究的目的是找出对Valganciclovir的治疗是否安全有效地防止患有CMV疾病风险的HIV感染患者的CMV器官损害。 符合条件的受试者将是CMV血清阳性，目前没有CMV预防，没有CMV终端器官疾病的证据，CD4细胞计数<100细胞/ mm3，血浆HIV RNA> 400份/ mL。 受试者在筛查时必须连续接受抗逆转录病毒疗法> 3个月，或者不接受抗逆转录病毒疗法，并且不打算在进行研究后至少3个月内启动抗逆转录病毒疗法。